Nephrogenic systemic fibrosis associated with gadolinium-containing contrast media administration in patients with reduced glomerular filtration rate [2]

Australasian Radiology

Volumn 51, Issue 3, 2007, Pages 300-

  Hedley, A J ^a   Molan, M P ^a   Hare, D L ^a   Anavekar, N S ^a   Ierino, F L ^a  

^a AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM; IODINE;

ALLERGY; ANGIOGRAPHY; DIAGNOSTIC PROCEDURE; DIALYSIS; FIBROSIS; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LETTER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; QUESTIONNAIRES; RARE DISEASES; RISK ASSESSMENT; RISK FACTORS; SKIN DISEASES;

EID: 34248403242     PISSN: 00048461     EISSN: 14401673     Source Type: Journal    
DOI: 10.1111/j.1440-1673.2007.01737.x     Document Type: Letter

References (3)

1. Marckmann P, Skov L, Rossen K et al. Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J. Am. Soc. Nephrol. 2006 17: 2359 62.
2. Grobner T. Gadolinium - A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol. Dial Transplant 2006 24: 1104 8.
3. United States Food and Drug Administration homepage on the Internet Rockville, Maryland, USA: United States Food and Drug Administration created 8 June 2006, cited 3 October 2006 Public Health Advisory Gadolinium-Containing Contrast Agents for Magnetic Resonance Imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance and MultiHance. Available from URL: http://www.fda.gov/cder/ drug/advisory/gadolinium_agents.htm.